Abstract
Introduction This study aimed to evaluate drug-drug interactions (DDIs) and their association with the quality of life in patients with hypertension. Materials and methods This cross-sectional study included 123 patients with hypertension. DDIs were evaluated using the Medscape Drug Interaction Checker Database (Medscape, New York, NY). The EuroQol-5D (EQ-5D) Quality of Life Scale was used for each patient. Results The overall blood pressure control rate (systolic/diastolic blood pressure levels, <140/90 mmHg) was 43% (53/123). The age of the patients with uncontrolled hypertension was higher than the patients with controlled hypertension (63.67 ± 11.00 vs. 58.42 ± 10.07 years; p = 0.007). The number of DDIs showed significant correlations, positively with age (r = 0.303, p = 0.001), total number of drugs (r = 0.784, p < 0.001), number of antihypertensive drugs (r = 0.640, p < 0.001), and body mass index (BMI) (r = 0.321, p < 0.001) and inversely with EQ-5D index score (r = -0.247, p = 0.006). The EQ-5D index and visual analog score were inversely correlated with age and BMI. Additional significant linear correlations between age and the total number of drugs, age and number of the antihypertensive drugs, the number of antihypertensive drugs and BMI, and the number of total drugs and BMI were detected. Of a total of 511 identified DDIs, 14 interactions in 12 patients were considered serious, 402 interactions in 82 patients were considered significant, and 95 interactions in 39 patients were considered minor. Conclusions This study supports that DDIs have important associations with antihypertensive treatment and the quality of life of patients. Higher age and BMI values were associated with a higher risk of DDIs and lower quality of life in patients with hypertension.